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1. Introduction 
Cancer is considered a disease of the genome since the development of the vast majority of 
the human neoplasias is due to the accumulation of gene mutations.  Indeed, the vast 
majority of tumours occur due to a considerable number of mutations that human cells 
accumulate during lifetime. Approximately 380 genes, representing about 1% of all human 
genes, have been implicated via mutation in tumorigenesis (Futreal et al., 2004). Most (90%), 
of these mutations are somatic, whereas germline mutations are a minority (20%). Some 
mutations may be both somatic and germline (10%) (Futreal et al., 2004). 
Pituitary adenomas (PA) are one of the most frequent intracranial tumours with a 
prevalence of clinically-apparent tumours close to one in 1,000 of the general population and 
are the third most common intracranial tumour type after meningiomas and gliomas 
(Scheithauer et al., 2006). The majority of pituitary adenomas are sporadic and only  a small 
subset (5% of all pituitary tumours) are familial, and often occur as component of familial 
endocrine-related tumour syndromes. Despite their benign nature, PA can cause significant 
morbidity because of hormonal hyper-secretion, or compressive effects to surrounding 
tissues. For example, GH-producing adenomas are associated with a GH excess that leads to 
gigantism or acromegaly, depending on whether  the excessive GH occurs prior or not to 
epiphyseal-plate closure, respectively. In addition, if the pituitary mass overgrows, it can 
impinge upon the optic chiasm interfering with vision or generally results in headache due 
to the increased pressure on the surrounding brain structures. 
Therefore, molecular understanding of pituitary adenoma formation is essential for the 
development of medical therapies and the treatment of post-operative recurrences. 
2. The pituitary gland 
The pituitary gland, also known as hypophysis, is one of the most important glands of the 
mammalian endocrine system. Through its secreted hormones, it controls the growth and 
activity of other glands: the thyroid, the adrenals, the gonads, the liver, the adipose tissue 
and the mammary glands (Fig. 1). The pituitary does not act independently, but it is under 
the continuous control of the nervous system through the hypothalamus. A wide range of 
external stimuli, including supply of nutrients, the ambient temperature, the exercise, and 
physical or psycological stress, causes secretion of hypothalamic hormones. As a response to 
hypothalamic control, the pituitary secretes the hypophyseal hormones, which maintain 
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crucial homeostatic functions, including metabolism, growth, and reproduction. Apart from 
the hypothalamic inputs, pituitary hormone secretion is also regulated by feedback effects of 
the circulating hormones, as well as the autocrine and paracrine secretions of the pituitary 
cells (Bilezikjian et al., 2004; Mechenthaler, 2008) (Fig. 1). 
 
 
Fig. 1. Schematic representation of the hypothalamic-pituitary axis. Hypothalamic 
hormones, through the portal system, directly target anterior pituitary cell surface receptors 
that elicit positive or negative signals mediating pituitary hormone gene transcription and 
secretion. Pituitary hormones exert negative feedback on hypothalamus. Intrapituitary 
cytokines and growth factors regulate pituitary cell function by paracrine and autocrine 
control. Peripheral hormones from pituitary target glands exert negative feedback on 
respective pituitary hormone synthesis and secretion as well as on hypothalamic releasing 
factors. a, testis; b, adipose tissue; c, ovary; d, mammary gland; e, thyroid; f, liver; g, adrenal 
glands (arrows). 
The human hypophysis is composed of the neurohypophysis (or posterior lobe) and the 
adenohypophysis (or anterior lobe). The posterior lobe consists of cells secreting antidiuretic 
(ADH) or vasopressin and oxytocin, whereas the anterior lobe is composed of five distinct 
cell types (Table 1). Approximately 50% of all anterior lobe cells are growth hormone (GH)-
secreting cells, also known as somatotrophs (Hearney & Melmed, 2004). GH has a crucial 
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role in controlling body growth and metabolism, by acting either directly on multiple tissues 
or indirectly, via the hepatic production of insulin-like growth factors (mainly IGF-1) (Brook 
& Marshall, 2001). Prolactin (PRL)-secreting cells, also known as lactotrophs, in men and 
nulliparous women may account for approximately 10% of the anterior pituitary cells, 
whereas in multiparous women their number can be up to three times higher (Heaney & 
Melmed, 2004). PRL inhibits the function of the gonads and stimulates breast enlargement 
and milk production during pregnancy. GH- and PRL-secreting cells derive from progenitor 
mammosomatotrophs, which are bi-hormonal cells that can differentiate into either 
somatotrophs or lactotrophs depending on the needs of each phase the body is in (i.e. 
growth, or pregnancy and lactation) (Asa & Ezzat, 2002). Adrenocorticotrophin (ACTH)-
secreting cells, also known as corticotrophs, account for approximately 10-20% of all anterior 
lobe cells (Heaney & Melmed, 2004). ACTH stimulates the secretion of glucocorticoid 
hormone (cortisol) from the adrenal gland cortex, while cortisol, in turn, concerts metabolic 
and anti-inflammatory effects (Goodman, 2003). Apart from ACTH, corticotrophs secrete 
endorphins, -lipotrophins and other pro-opiomelanocortin derivatives. 
Follicle stimulating hormone (FSH) and luteinizing hormone (LH)-secreting cells, or 
gonadotroph cells, account for roughly equal numbers as corticotrophs (Heaney & Melmed, 
2004). These hormones regulate the sex steroid hormone production in the gonads, as well 
as the development and maturation of the germ cells. Lastly, a small percentage of 
thyrotroph cells (5%) secrete the thyroid stimulating hormone (TSH) (Heaney & Melmed, 
2004). TSH is the stimulus for thyroid hormone (T3/T4) production from the thyroid gland. 
Thyroid hormone mainly controls GH synthesis and secretion, metabolism and 
thermogenesis, as well as foetal skeletal maturation, and central nervous system 
development and maturation (Goodman, 2003). 
 
Pituitary cells Secreting hormone Target tissue 
Corticotrophs Adrenocorticotropic hormone (ACTH) Adrenal gland 
Gonadotrophs 
Follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH) 
Ovary, Testis 
Somatotrophs Growth hormone (GH) Liver, adipose tissue 
Lactotrophs Prolactin 
Ovary, mammary 
gland 
Thyrotrophs Thyroid-stimulating hormone (TSH) Thyroid gland 
Table 1. Anterior pituitary cell functions 
3. Origin and development of pituitary adenomas 
Pituitary tumours are believed to develop by monoclonal expansion of a single neoplastic 
cell, due to an acquired intrinsic primary cell defect (genetic or epigenetic) that confers 
growth advantage (Asa & Ezzat, 2002). Indeed, early molecular studies of pituitary tumours, 
employing X-chromosome inactivation as a means of determining clonality, show that, in 
most cases, these tumours are monoclonal in origin, suggesting an intrinsic discrete 
genetic/molecular defect driving the transforming event and perhaps other ones driving 
progression (Fig. 2). However, these tumours do not follow the sequential classic paradigm 
apparent in multiple other tumour types, that is, initiation/transformation, hyperplasia, 
benign adenoma, invasive/aggressive adenoma and, ultimately, carcinoma. Conversely, 
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they can arise from a hyper-plastic pituitary tissue, in which there are a number of different 
clones each with variable potential to develop into a discrete tumour. Consistent with this 
hypothesis is the finding of different patterns of genetic alterations in recurrent/re-grown 
tumours compared to primary PA from the same patient (Clayton et al., 2000). Therefore, 
alongside the monoclonal hypothesis, more recently the polyclonal hypothesis has been 
proposed. According to it PA originate from the expansion of a single clone coming from a 
polyclonal hyper-plastic tissue. The initiating stimulus, which might include pituitary-
specific oncogenes, intra-pituitary growth factors, or hypothalamic releasing hormones, 
would result in hyperplasia of specific cell subtypes in the pituitary giving rise to a number 
of different clones each one with variable potential to develop into a discrete tumour 
(Clayton & Farrell, 2004) (Fig. 2).  
 
 
Fig. 2. Schematic representation of the two models of PA genesis (monoclonal and 
polyclonal hypotheses) 
Pituitary tumours are in most of the cases benign and can grow both slowly and 
expansively. However, although defined as benign, nearly 50% of PA invade surrounding 
tissues, but invasiveness rate differs between various PA types (Brook & Marshall, 2001; 
Saeger et al., 2007), and mitotic activity is low even in aggressive PA, in contrast to tumours 
arising from more rapidly replicating tissues (Melmed, 2003). Very rarely PA become 
metastatic, and are then referred as pituitary carcinomas. Their incidence has been 
suggested to be 0.2% of symptomatic pituitary tumours (Pernicone et al., 1997), with almost 
equal frequency in both sexes (DeLellis et al., 2004; Kaltsas et al., 2005). Most are ACTH- or 
PRL-secreting tumours (Saeger et al., 2007). The time interval between initial adenoma 
diagnosis and carcinoma development may vary greatly, depending on the tumour subtype, 
with a mean of seven years (Pernicone et al., 1997; Sidibe, 2007). The reason of the unique 
feature of PA to rarely progress to carcinomas has been recently attributed to “premature” 
senescence-associated molecular pathways activated in PA (Chesnokova & Melmed, 2010). 
Premature senescence is a mechanism of irreversible cell cycle arrest and constitutes a 
strong anti-proliferative response, which can be triggered by DNA damage, chromosomal 
instability and aneuploidy, loss of tumour suppressive signalling or oncogene activation 
(Sharpless & Depinho, 2004). It occurs in benign or early stage tumours, but not in the 
advanced ones, as a mean to buffer the cell from pro-proliferative signals (Michaloglou et 
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al., 2005, as cited in Chesnokova & Melmed, 2010), and functions to protect against 
oncogenic transformation, thereby suppressing unscheduled proliferation of damaged and 
early transformed cells.  
4. Classification and pathogenesis of sporadic pituitary adenomas 
Sporadic PA account for 10-15% of diagnosed brain tumours and although some differences 
in their frequencies exist, each of the five hormone-secreting cell types within the gland can 
give rise to an adenoma (Table 2) (Asa & Ezzat, 2002; Melmed, 2003). Apart from these 
adenomas, which are easily diagnosed upon the appearance of the clinical symptomatology 
consequent to the specific hormone hyper-secreted,  micro-adenomas, known as 
“incidentalomas”, are present in 10% of the general population and are encountered 
inadvertently by MRI (Melmed & Kleinberg, 2008). Micro-adenomas are intra-sellar and 
generally less than 10 mm in widest diameter. Macro-adenomas, mainly including non 
functioning pituitary adenomas (NFPA), are greater than 10 mm and usually impinge upon 
adjacent sellar structures determining mass effects, including pituitary failure, blindness, 
headache and various CNS disorders. Immunocytochemistry detects pituitary cell gene 
products and allows classification of pituitary tumours based on their function (Table 2). 
With the only exception of the glycoprotein -subunit (-GSU), immunohistochemical 
positivity of more than 5% of cells in the tumour usually reflects peripheral circulating 
hormone levels (Melmed & Kleinberg, 2008). 
 
Adenoma type Incidence 
Principal hormone 
immunoreactivity 
Clinical 
manifestation 
Prolactinoma 29% Prolactin 
Hypogonadism, 
galactorrhea 
NFPA 
(gonadotroph and null-
cell adenoma) 
27% FSH/LH/-GSU Mass effects 
Somatotropinoma 15% GH 
Gigantism or 
acromegaly 
Adrenocorticotropinoma 10% ACTH Cushing’s disease 
Mixed GH/PRL cell 
adenoma 
5% GH/prolactin 
Hypogonadism, 
acromegaly, 
galactorrhea 
Mammosomatotroph cell 
adenoma 
1% GH/prolactin 
Hypogonadism, 
acromegaly, 
galactorrhea 
Thyrotroph cell adenoma 0,9% TSH Hypothyroidism 
Table 2. Clinical and pathological characteristics of pituitary adenomas (adapted from 
Melmed & Kleinberg, 2008) 
A considerable literature details the pathogenic changes occurring in sporadic tumours. 
However, in marked contrast to most other tumour types, there are few reports that describe 
genetic mutations (either activating oncogenes or inactivating tumour suppressor genes) 
that “drive” the inappropriate proliferation of pituitary cells. More often, altered control of 
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gene expression, which results in either over-expression or down-regulation of certain 
proteins, is involved in PA pathogenesis. These proteins include hormones, growth factors, 
their receptors, the associated signal transduction pathways, cell-cycle regulators and factors 
involved in chromosomal instability. 
4.1 Gain-of-function mutations 
Oncogenes commonly mutated in the majority of human tumours are very rarely involved 
in pituitary tumorigenesis. Indeed, apart from GNAS and HMGA2 genes that are mutated in 
a considerable percentage of GH-secreting adenomas and prolactinomas, respectively, few 
gain-of-function mutations have been reported in PA.  
4.1.1 GNAS 
Activating gsp mutation is present in up to 40% of human GH-secreting adenomas (Lyons et 
al., 1990). They consist in somatic heterozygous point mutations of the G protein -subunit 
(Gs) gene (GNAS) involving either arginine 201 (replaced with cysteine or histidine) or 
glutamine 227 (replaced with arginine or leucine) that constitutively activate the Gs protein 
(Vallar et al., 1987). Similar early post-zygotic somatic mutations in codon 201 of the Gs 
were identified in tissues derived from patients with McCune-Albright syndrome (MAS), 
which includes GH-secreting pituitary adenomas (Weinstein et al., 1991). Interestingly, only 
in the pituitary the Gs expression is mono-allelic - subject to imprinting - and is derived 
from the maternal allele (Hayward et al., 2001). When expressed in cell lines, mutant Gs 
showed a 30-fold decrease in the rate of  subunit-mediated hydrolysis of GTP to GDP, a 
mechanism required to turn-off its activation (Landis et al., 1989). The resulting G protein 
activation increases cyclic adenosine mono-phosphate (cAMP) levels and activates protein 
kinase A (PKA), which in turn phosphorylates the cAMP response element-binding protein 
(CREB) and leads to sustained constitutive GH secretion and cell proliferation.  
The gsp mutations have been identified also in NFPAs and ACTH-secreting adenomas 
(<10%), but quite rarely and not in all the studies (Melmed & Kleinberg; Lania et al., 2003).  
4.1.2 GNAI2 
Activating gip mutations, involving the GNAI2 gene that encodes a G protein subunit 
involved in the inhibition of adenylyl ciclase and calcium influx, have been observed in a 
subset of NFPAs (Williamson et al., 1994). The mutation, observed in 3 out of 22 samples 
(13%), consists in an aminoacid substitution that replaces Gln 205 (corresponding to Gln 227 
of Gs) with Arg, which causes activation of Ras (Edamatsu et al., 1998). Interestingly, two 
tumours with gip mutations also harboured gsp mutations, suggesting the possibility of 
multiple hits in a stepwise pathogenesis of pituitary neoplasia (Williamson et al., 1994).   
4.1.3 RAS 
The family of RAS genes encodes a 21-kD monomeric GDP/GTP binding protein mainly 
involved in the transduction of growth factor signalling. These genes may acquire mitogenic 
properties by point mutations that increase the affinity for GTP in the GTP-binding domain 
(codons 12 and 13) or prevent GTP-ase activity (codon 61). These mutations are present with 
high frequency in human neoplasias but are very rare in pituitary tumours (Karga et al., 
1992; Cai et al., 1994; Pei et al., 1994, as cited in Lania et al., 2003). Indeed, a Gly12 to Val 
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substitution has been observed in one aggressive prolactinoma resistant to dopaminergic 
inhibition that eventually was lethal. RAS mutations have been also described in metastases 
of three pituitary carcinomas, but not in the primitive tumours (Lania et al., 2003). Therefore, 
the rare RAS mutations in pituitary tumours are associated with malignant features, likely 
representing a late event in pituitary tumorigenesis. 
4.1.4 PKC 
The Ca2+/calmodulin and phospholipid-dependent protein kinase C (PKC) is a large 
ubiquitous kinase family that participates in growth factor- and hormone-mediated 
signalling and cell proliferation. Point mutations in the gene encoding the PKC isoform, 
replacing Gly294 with Asp - a strategic region of PKC containing the calcium-binding site -
have been observed in four invasive pituitary tumours (Alvaro et al., 1993), causing its over-
expression with respect to normal pituitary. These findings were not confirmed by 
subsequent studies (Schiemann et al., 1997), but ectopic expression of a mutant form of 
PKC originally found in human tumours leads to aberrant sub-cellular translocation of the 
enzyme, together with effects on growth control (Alvaro et al., 1997).  
4.1.5 FGFR4 
The normal pituitary and pituitary tumours produce a wide number of substances with 
secretory, differentiating, and proliferative potentials and express specific receptors (Lania 
et al., 2003). The aberrant expression of an N-terminally truncated fibroblast growth factor 
(FGF) receptor-4, containing the third Ig-like domain, the trans-membrane region and the 
kinase domain,  that is constitutively phosphorylated and causes transformation in vitro and 
in vivo, has been reported in about 40% of pituitary adenomas, composed of the various 
hormone-secreting cell types, but not in normal pituitary. Consistently, the expression of 
this truncated receptor in lactotroph pituitary cells of transgenic mice results in the 
development of PA (Ezzat et al., 2002). 
4.1.6 HMGA2 
The HMGA2 protein belongs to the High Mobility Group A (HMGA) family, also including 
HMGA1, composed of small, non-histone, chromatin-associated proteins that alter the 
architecture of chromatin and facilitate the assembly of multi-protein complexes of 
transcriptional factors (Thanos & Maniatis, 1995). These functions have important rebounds in 
a wide spectrum of biological processes, ranging from embryonic development, cell 
differentiation and transformation, cell cycle progression, apoptosis, senescence, DNA repair, 
up to different aspects of cell physiopathology, including body growth, cardiogenesis, self-
renewal of neural stem cells, inflammation and cancer (Hock et al., 2007; Fedele et al., 2010). 
The HMGA2 gene is over-expressed in human prolactinomas (Finelli et al., 2002). Its over-
expression is associated, in most of the prolactin-secreting adenomas analised, with gain of 
chromosome 12 (trisomy/tetrasomy), the most frequent cytogenetic alteration in these 
tumours, and amplification of the HMGA2 locus (region 12q13-15) or structural 
rearrangements of chromosome 12 (Finelli et al., 2002).  
HMGA2 over-expression was also found in 12 out of 18 NFPA, which rarely harbour 
trisomy 12 but, differently from what occurs in prolactinomas, HMGA2 up-regulation was 
associated with amplification and/or rearrangement of the HMGA2 locus in only two cases 
(Pierantoni et al., 2005). 
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It is noteworthy that animal models clearly identified a critical role for HMGA genes in 
pituitary tumorigenesis since, as more deeply described below, transgenic mice over-
expressing either the Hmga1 or the Hmga2 genes develop mixed prolactin/GH-secreting 
adenomas with a high penetrance  (Fedele et al., 2002; 2005).   
4.2 Loss-of-function mutations 
Aberrant pituitary cell proliferation may result from the inactivation of either common 
tumour suppressor genes (TSGs) or specific inhibitors of pituitary cell function and growth. 
Unlike oncogenes that drive neoplastic transformation also when mutated in 
heterozygosity, TSGs are usually recessive and the inactivation of both alleles is required to 
cause the loss of anti-tumoral action.  
Even though the key role of some TSGs (p27kip1, RB) in pituitary tumorigenesis has been 
clearly demonstrated in mice (Fero et al., 1996; Jacks et al., 1992, as cited in Fedele & Fusco, 
2010), they are not or very rarely mutated in human PA.  
Low expression levels of p27Kip1 protein have been found in ACTH-secreting adenomas, 
recurrent PA, and pituitary carcinomas by immunohistochemistry. However, as it occurs in 
other human neoplasias, no changes in p27kip1 mRNA levels were observed, suggesting the 
involvement of post-translational mechanisms accounting for the impairment of p27kip1 
protein stabilization in these tumours (Dahia et al., 1998). 
Recently, reduced p27kip1 protein levels were found in a NFPA harbouring a novel mutation 
of DKC1, encoding for dyskerin, a pseudouridine synthase that modifies rRNA and 
regulates telomerase activity. This mutation, consisting in a specific aminoacid substitution 
(S485G), significantly alters DKC1 stability/pseudouridylation activity (Bellodi et al., 2010). 
However, the link between DKC1 mutation and p27kip1 expression is not clear yet. 
Loss of heterozygosity (LOH) on chromosome 13q14, where RB is located, is a relatively 
frequent event. In particular, deletion of one RB allele is observed in most highly invasive or 
malignant pituitary tumours and their metastases. The retained allele is not mutated but, as 
better described below, it is frequently hyper-methylated (Pei et al., 1995; Simpson et al., 
1999; 2000, as cited in Lania et al., 2003). However, the presence of cases of LOH at 13q14 in 
PA in the absence of mutation or hyper-methylation of the RB allele may suggest the 
involvement in PA of another still unknown TSG  located in the same chromosomal region 
(Bates et al., 1997, as cited in Vandeva et al., 2010). 
MEN1 gene mutations, responsible for  the MEN-1 syndrome (fully described in paragraph 
5.1), are uncommon in sporadic PA (~3%), even in the presence of LOH of 11q13 (Melmed & 
Kleinberg). Indeed, just four cases have been described: in one NFPA,  in one ACTH-
secreting adenoma (Zhuang et al., 1997), in one prolactinoma (Wembin et al., 1999) and in 
one TSH-secreting adenoma (Schmidt et al., 1999), suggesting, also in this case, the presence 
of another adenoma-relevant TSG on chromosome 11. 
More recently, the aryl hydrocarbon receptor interacting protein (AIP) gene, also located on 
chromosome 11q13 and responsible for familial isolated pituitary adenomas (fully described 
in paragraph 5.4), has been found to be mutated in about 3% of sporadic GH-secreting 
adenoma (Occhi et al., 2010). The AIP protein is a co-chaperone and though to be important 
in keeping proteins and protein complexes in functional formation. It interacts with several 
protein partners, including hydrocarbon receptor, phosphodiesterases, survivin, G proteins 
and RET, and currently it is uncertain which of them plays a key role in pituitary 
tumorigenesis. The AIP mutation types identified in sporadic PA include nonsense, splice 
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site substitutions, missense, frameshift and in-frame deletions. Some of them have been only 
identified in sporadic PA, whereas some others have been identified in both familial and 
sporadic cases (Ozfirat & Korbonits, 2010). 
Interestingly, no mutations in the TP53 gene have been found in PA, even though they have 
been detected in more than 50% of all human cancers, including tumours of the central 
nervous system (Lania et al., 2003). Since TP53 mutations are associated with tumour 
progression, this result appears consistent with the intrinsic nature of pituitary tumour 
evolution, which rarely progress to carcinoma.  
 
Pituitary tumour type Mutated gene Incidence 
GH-secreting 
NFPA/ACTH-secreting 
GNAS 
40% 
<10% 
NFPA GNAI2 13% 
Pituitary carcinomas/invasive prolactinomas RAS rare 
Invasive NFPA PKC rare 
All types FGFR4 ~40% 
Prolactinomas 
NFPA 
HMGA2 
~80% 
~10% 
NFPA, ACTH-secreting, prolactinoma, TSH-
secreting 
MEN1 ~3% 
GH-secreting AIP ~3% 
NFPA DKC1 rare 
Table 3. Summary of gene mutations and their incidence in sporadic pituitary adenomas.  
4.3 Gene over-expression 
To identify novel factors involved in pituitary tumour pathogenesis, several studies have 
been focused on differences in gene expression between PA and normal pituitary tissue. 
Indeed, more frequently than gene mutations, alterations of gene expression have been 
reported in human PA. They include both gene over-expression and down-regulation, the 
latter being mainly associated with epigenetic gene silencing.  
4.3.1 Cyclins 
Cell cycle dysregulation is the main pathogenetic event in the development of pituitary 
tumors. In fact, it has been estimated that more than 80% of human pituitary tumours 
display alterations at least in one of the regulators of the G1/S transition of the cell cycle 
(Malumbres & Barbacid, 2001, as cited in Fedele & Fusco, 2010). In particular, over-
expression of different cyclins has been reported in various functioning and non functioning 
PA. 
Cyclin E expression is increased in ACTH adenomas compared to normal pituitary tissue 
(Jordan et al., 2000, as cited by Fedele & Fusco, 2010), likely related to the low levels of 
nuclear p27kip1 in these tumours (Musat et al., 2010). 
Cyclin D1, as well as cyclin D3, is over-expressed in aggressive NFPA (Jordan et al., 2000, 
Turner et al., 2000, Saeger et al., 2001, Simpson et al., 2001, as cited in Fedele & Fusco, 2010). 
One of the possible mechanisms responsible of such over-expression could be the activation 
of the Wnt--catenin pathway that targets cyclin D1. Indeed, transfecting GH3 pituitary cells 
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with Wnt inhibitory factor-1 (WIF1) decreased cell proliferation and colony formation, 
suggesting an involvement of Wnt pathway in pituitary tumorigenesis (Elston et al., as cited 
in Musat et al., 2010). Moreover,  cyclin D1 gene allelic imbalance has been described in 
about 25% of analysed adenomas (Hibberts et al.,1999, as cited in Fedele & Fusco, 2010). 
B-type cyclins have recently been found over-expressed in many human pituitary 
adenomas, with prevalence in prolactinomas (Wierinckx et al., 2007; De Martino et al., 2009). 
4.3.2 PTTG 
Pituitary tumour transforming gene (PTTG) was isolated from experimental pituitary 
tumours by mRNA differential display PCR between rat pituitary tumor cells and normal 
pituitary tissue (Pei & Melmed, 1997). Subsequent experiments showed its abundant 
expression in nearly all pituitary tumour types, especially prolactinomas, but not in normal 
pituitary (Zhang et al., 1999).  
PTTG codes for securin that interacts and inhibits the proteolitic protein separase, which 
degrades the cohesin complex involved in holding together replicated paired sister 
chromatids during metaphase, leading, when over-expressed, to cell aneuploidy, which is 
frequently observed in PA (Uhlmann et al., 1999; Zou et al., 1999, as cyted by Fedele & 
Fusco, 2010). In addition, PTTG also induces FGF production and angiogenesis and is up-
regulated by oestrogen (Melmed & Kleinberg, 2008) and modulates the G1/S phase 
transition by interacting with Sp1 and regulating the transcriptional activity of the cyclin D3 
promoter (Tong et al., 2007, as cyted by Fedele & Fusco, 2010).  Interestingly, PTTG is 
regulated by CDK1-mediated phosphorylation suggesting a link between the control of the 
cell cycle by CDKs and securin function (Holt et al., 2008, as cyted by Fedele & Fusco, 2010). 
Finally, PTTG has been implicated in the premature senescence that typically characterizes 
PA and that is responsible for the benign nature of this tumour (see paragraph 3). Indeed, 
both PTTG deletion and over-expression cause extensive pituitary cell aneuploidy, which 
causes intracellular p53 accumulation and p21 induction, resulting in senescence 
(Chesnokova & Melmed, 2010).  Therefore, high PTTG levels in PA may initially mediate 
excessive proliferation, and lead to defective DNA replication and aneuploidy. Activation of 
pituitary DNA damage pathways triggers p21, a barrier to tumour growth, which in turn 
may restrain further growth and malignant transformation (Chesnokova & Melmed, 2010). 
4.3.3 HMGA1 and HMGA2 
Both HMGA1 and HMGA2 genes are over-expressed in different subtypes of PA, with the 
highest levels in prolactin- and/or GH-secreting tumours, compared to normal pituitary (De 
Martino et al., 2009). In addition, HMGA1 expression is significantly higher in invasive 
adenomas or macro-adenomas than in non-invasive adenomas or micro-adenomas and 
shows the highest level in grade IV, more aggressive pituitary adenomas, than in grades I, II 
and III (Wang et al., 2010). However, while HMGA2 over-expression is associated to gene 
amplification (see paragraph 4.1.6), HMGA1 over-expression does not appear to depend 
upon cytogenetic alterations involving the 6p21 chromosomal region, where the HMGA1 
gene is located (Fedele et al., 2010).  
Studies in mice over-expressing either Hmga1 or Hmga2 gene under the transcriptional 
control of the cytomegalovirus promoter, clearly demonstrated the causal role of both these 
genes in pituitary tumorigenesis. Indeed, both these transgenic mouse models, with 
different incidence and latency period, develop mixed GH/PRL-secreting PA (Fedele et al., 
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2002; 2005). The mechanism by which HMGA proteins induce the onset of PA mainly 
involves the interaction with pRB, which causes the displacement of HDAC1 from the 
pRB/E2F1 complex, and the resulting enhancement of E2F1 activity (Fedele et al., 2006). The 
crucial role of the HMGA-mediated E2F1 activation in pituitary tumorigenesis was 
confirmed by crossing Hmga2-overexpressing with E2f1-knockout mice, which resulted in 
the suppression of pituitary tumorigenesis in double mutant mice (Fedele et al., 2006). The 
analysis of the expression profile of pituitary adenomas developed by Hmga transgenic 
mice in comparison with normal pituitary from wild-type mice led to the identification of 
other genes potentially down-stream in the molecular pathway leading to PA onset in 
Hmga transgenic mice (De Martino et al., 2007; 2009). Among these genes, Mia/Cd-rap, 
coding for a secreted product of malignant melanoma cells, and Ccnb2, encoding the cyclin 
B2, which plays an important role in cell cycle progression, are directly regulated, by the 
HMGA proteins at transcriptional level (De Martino et al., 2007; 2009). Consistent with these 
data, the MIA gene, which is down-regulated by HMGA proteins, is down-regulated in 
human prolactinomas compared to normal pituitary (Evans et al., 2008), and the CCNB2 
gene, which is up-regulated by HMGAs, is over-expressed in PA versus normal pituitary, in 
statistically significant association with HMGA expression (De Martino et al., 2009). 
4.3.4 Galectin 3 
Recent evidences suggest that galectin-3 (Gal-3), a member of a phylogenetically conserved 
family of lectins sharing a consensus sequence of about 130 amino acids and a carbohydrate-
recognition domain responsible for -galactosides binding, plays an important role in 
pituitary progression (Righi et al., 2010). Gal-3, encoded by the LGALS3 gene on 
chromosome 14q21-22, is ubiquitously expressed mainly in the cytosol, but it can easily 
traverse the intracellular and plasma membranes. Extracellular Gal-3 mediates cell 
migration, cell adhesion, and cell-to-cell interactions, whereas intracellular Gal-3 inhibits 
apoptosis and is up-regulated during neoplastic progression and metastasis in several 
human cancer (Righi et al., 2010). In different studies, Gal-3 expression was  reported in 
folliculo-stellate cells and in normal and neoplastic pituitary prolactin- and ACTH-secreting 
cells, with a significantly higher presence in carcinomas versus adenomas (Riss et al., 2003; 
Ruebel et al., 2006, as cited in Righi et al., 2010). Indeed, down-regulation of Gal-3 , by RNA 
interference induced a significant decrease in cell proliferation and an important increase in 
apoptosis of pituitary HP75 cells (Riss et al., 2003, as cited in Righi et al., 2010), indicating a 
causal role of Gal-3 expression in pituitary tumorigenesis. 
Recent studies suggest that the consequences of Gal-3 over-expression in pituitary 
carcinoma development could be related to changes in the expression levels of cell cycle 
targets of the Wnt/-catenin signalling pathway, such as cyclin D1 and the proto-oncogene 
c-myc (Kim et al., 1999; Lin et al., 2000; Shimura et al., 2004, as cited in Righi et al., 2010).  
4.4 Gene down-regulation and epigenetic gene silencing 
For many of the genes whose expression is lost or drastically reduced in PA versus normal 
pituitary, the epigenetic gene silencing is the common mechanism . 
The term epigenetic refers to a process that heritably influences the expression of a gene 
without genetic change to the underlying DNA sequence itself (Jaenish & Bird, 2003). The 
silencing of TSGs, through or associated with CpG island methylation, is recognized as a 
major mechanism of gene inactivation that frequently coexists with genetic lesions in most 
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cancers studied to date (Esteller, 2007). It has been proposed that methylation silences gene 
expression by hindering the access of transcription factors to their binding sites. 
Additionally, it is proposed that silencing might be achieved by methyl-binding proteins 
that recruit chromatin-modifying factors that compact and inactivate the chromatin (Tateno 
et al., 2010). The epigenetic events involved in pituitary tumorigenesis that lead to down-
regulation of gene and/or protein expression are mainly due to promoter hyper-
methylation and/or microRNA (miRNA)-dependent impairment of protein translation.  
In the following subsections we will describe the main genes down-regulated by promoter 
methylation in PA compared to normal pituitary tissue. 
4.4.1 Cell cycle inhibitors 
The retinoblastoma (pRB) family members are the main inhibitors of cell cycle progression 
from G1 to S phase. Even though heterozygous pRb-knockout mice develop PA, no 
mutations at the RB gene have been so far found in human pituitary tumours. However, 
lack of expression of pRB has been found in a small number of pituitary tumours where the 
promoter region of RB is hyper-methylated (Simpson et al., 2000).  
Hyper-methylation of the promoter region also accounts for the loss of p16INK4 protein 
expression, which is relatively frequent in PA (Simpson et al., 1999). RB and p16INK4a 
methylations tended to be mutually exclusive (Yoshino et al., 2007). 
As for pRB and p16INK4a, down-regulation of p21Cip1 and p27kip1 in pituitary adenomas may 
also be due to epigenetic modifications, including DNA and/or histone methylation 
(Yoshino et al., 2007, Zhu et al., 2008). 
4.4.2 Hypotalamic hormone receptors  
Somatostatin (SS) and dopamine (DA) are among the key regulators of hormone secretion 
by the anterior pituitary gland. SS mediates its inhibitory activity on pituitary hormone 
secretion via specific seven trans-membrane G-protein coupled SS receptors (sst). Human 
adult pituitary tissue expresses sst1, sst2, sst3 and sst5. Similarly, DA action is mediated by 
five receptors, named D1, D2, D3, D4 and D5, being D2 the only one highly expressed in 
pituitary cells (lactotroph and non-lactotroph). DA and SS receptors can form heterodimers 
that may have influence on ligand binding, signalling and internalization of the respective 
receptors (Hofland et al., 2010).  
The expression of sst subtypes in human PA is different in comparison with pituitary and 
from tumour to tumour. GH-secreting adenomas display a predominant expression of 
sst2 and sst5, whereas a subset of GH-secreting adenomas expresses sst1 and sst3 as well. 
In prolactinomas, sst1 and sst5 are the predominantly expressed ssts, whereas sst2 is 
expressed at a detectable level in only a minority of them. ACTH-secreting adenomas 
express sst5 at highest level, and most of them co-express sst2 at low level. Silent 
corticotroph adenomas display considerable higher sst1 and sst2, but lower sst5 
expression, compared with ACTH-secreting PA. NFPA mainly express sst3 and to a lesser 
degree sst2. In TSH-secreting PA, sst2 is mainly expressed, with co-expression of sst3 and 
sst5 in a subset. Finally, two novel truncated isoforms of sst5 (sst5MD5 and sst5MD4) with 
five and four trans-membrane domains, respectively, have been identified in PA. In 
particular,  sst5MD4 was found in 85% of GH-secreting adenomas and its expression was 
negatively associated with the inhibitory effect of octreotide on circulating GH levels in 
vivo (Hofland et al., 2010).  
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The differential expression of specific sst subtypes in PA may be caused by epigenetic 
events. Indeed, it has been recently identified an upstream promoter of the human 
somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications, including 
DNA methylation and histone acetylation (Torrisani et al., 2008).  
As far as DA receptor expression, mainly D2 has been demonstrated in the majority of PA, 
although expression levels may vary among adenomas. Interestingly, the loss of D2 
expression correlates with  increased CpG island-associated methylation and enrichment for 
histone H3K27me3. Conversely, D2 expression is associated to enrichment for H3K9Ac and 
barely detectable H3K27me3 (Al-Azzawi et al., 2011).  
Therefore, a combined treatment with epigenetic drugs and DA agonists for the medical 
management of different pituitary tumour subtypes, resistant to conventional therapies, 
could be envisaged. 
4.4.3 GADD45 
One of the growth inhibitory genes whose expression is lost in the majority of human PA is 
GADD45, a p53-regulated gene involved in inhibition of cell growth. Indeed, it was found 
abundantly expressed in normal pituitary and strongly down-regulated in different PA sub-
types. Moreover, suppression of cell proliferation was observed when GADD45 was 
expressed in pituitary cell lines (as reviewed by Zhang et al., 2010), suggesting a causal role 
of its loss in pituitary tumorigenesis. The loss of GADD45 expression in pituitary tumour 
cells has been associated with methylation of the GADD45 CpG island, frequently (58%) 
reported in PA not expressing the GADD45  gene (Bahar et al., 2004). 
4.4.4 MEG3 
The Maternally Expressed Gene 3 (MEG3), a large maternal imprinted non-coding RNA gene 
located on chromosome 14q32, is highly expressed in the pituitary but specifically absent in 
gonadotroph-derived NFPA (Zhang et al., 2010). No gene deletion or mutation at the MEG3 
gene was found in such tumours, but increased DNA methylation in promoter and enhancer 
regions, responsible for loss of MEG3 expression, was identified in tumours in comparison 
with normal pituitary (Zhao et al., 2005).  
MEG3 is able to suppress proliferation of different types of human tumour cells due to its 
ability to act up-stream of two well known TSGs, such as p53 and pRB. Indeed, MEG3 
stimulates p53-mediated transcriptional activation of specific targets, such as GDF15, a TGF-
 family member with an anti-proliferative activity, and leads to the accumulation of p53 
protein levels. However, it can also suppress cell proliferation in the absence of p53 through 
a pRB-dependent mechanism (Zhou et al., 2007, as cited in Zhang et al., 2010). 
4.4.5 ZAC1 
The zinc-finger protein ZAC1 is a transcription factor and co-regulator that plays a key role 
in pituitary development, maturation and tumorigenesis. Indeed, it lies downstream to the 
mitogenic MAPK and survival PI3K pathways, and its target genes control cell proliferation 
and hormone synthesis of pituitary cells (Theodoropoulou et al., 2010). As co-regulator, 
ZAC1 is involved in the activation of different members of the nuclear receptor and p53 
family (Huang & Stallcup, 2000; Huang et al., 2001, as cited in Theodoropoulou et al., 2010), 
which are key regulators of cell growth, differentiation, homeostasis and development. In 
particular, through activation of p53, ZAC1 induces the cell-cycle inhibitor p21Cip1 causing 
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growth arrest. Moreover, ZAC1 can also directly bind to the proximal promoter of p21Cip1 
and confer trans-activation to the GC-rich Sp1-responsive elements (Huang et al., 2007, as 
cited in Theodoropoulou et al., 2010). 
ZAC1 is highly expressed in all types of hormone-producing pituitary cells (Pagotto et al., 
2000, as cited in Theodoropoulou et al., 2010). The chromosomal region where it maps 
(6q24-25) is frequently deleted in solid tumours, and LOH at least at one informative marker 
has been reported in 50% of pituitary adenomas analysed, but no mutations in the ZAC1 
coding region have been found (Pagotto et al. 2000, as cited in Theodoropoulou et al., 2010). 
However, ZAC1 mRNA and protein levels were found reduced in all types of PA, especially 
in null cell NFPA, where ZAC1 expression may be completely absent, suggesting a putative 
role of ZAC1 in pituitary differentiation, since null cell adenomas are thought to be de-
differentiated tumours (Theodoropoulou et al., 2010).  
It is likely that the loss of ZAC1 expression may be due to an aberrant methylation of a 5’-
CpG island in the ZAC1/LOT1 gene, since it has been reported that this region is 
differentially methylated in ovarian and breast cancer compared to normal tissues 
(Abdollahi et al., 2003). Moreover, histone deacetylation, elicited by a mechanism up-stream 
of the LOT1 gene, has been suggested as an additional epigenetic modification that controls 
ZAC1 expression (Abdollahi et al., 2003). 
4.5 microRNA expression in pituitary adenomas 
MicroRNAs (miRNAs/miRs) are a huge class of non-coding small RNAs that post-
transcriptionally regulate gene expression by targeting the 3’ un-translated mRNA regions. 
miRNAs control a wide range of biological functions, including cell proliferation, 
differentiation, apoptosis and metabolism, and are involved in human pathology, including 
cancer (Bartel, 2004). Indeed, it has been suggested that some miRNAs might have 
oncogenic or tumour suppressor functions, playing key roles in tumorigenesis (Croce, 2009).  
In PA of different histotypes, a significant down-regulation of miR-15a and miR-16-1, that 
inversely correlates with tumour diameter and directly correlates with the secretion of the 
anti-neoplastic cytokine p43, has been shown in comparison with normal pituitary (Bottoni 
et al., 2005).  
The analysis of the differential expression profile of PA of specific histotypes in comparison 
with normal pituitary, has identified several other miRNAs potentially involved in pituitary 
tumorigenesis (Bottoni et al., 2007; Amaral et al., 2009; Mao et al., 2010). In ACTH-secreting 
adenomas six more miRNAs (miR-145, miR-21, miR-141, let-7a, miR-150 and miR-143), other 
than miR-15a and miR-16, have been shown to be down-regulated (Amaral et al., 2009). In 
GH-secreting adenomas 52 miRNAs have been reported to be differentially expressed (23 
up-regulated and 29 down-regulated). Nine of them are differentially expressed between 
micro- and macro-adenomas (Mao et al., 2010). Also in NFPAs, six miRNA, including miR-
140, miR-99b, miR-99a, miR-30c, miR-30b and miR-138-2, (the first five up-regulated and the 
last one down-regulated) are differentially expressed in macro- versus micro-adenomas 
(Bottoni et al., 2007).  
Interestingly, most of the identified miRNAs differentially expressed in PA versus normal 
pituitary tissue are involved in cell growth, apoptosis, cell proliferation and tumour 
development. In particular, miR-126 and miR-381, both down-regulated in 
somatotropinomas, target PTTG (Mao et al., 2010). Furthermore, recent studies have 
demonstrated that the down-regulation of five miRNAs (let-7, miR-15, miR-16, miR-26 and 
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miR-196a-2), able to target the HMGA proteins, plays a key role in pituitary tumorigenesis 
(De Martino et al., 2009b; Kaddar et al., 2009; Quian et al., 2009; Palmieri et al., manuscript in 
preparation, as cited in Fedele et al., 2010). 
Therefore, an innovative therapeutic approach for PA could be the use of miRNAs able to 
target proteins playing key role in pituitary tumorigenesis and whose expression is down-
regulated in PA. Indeed, such approach has been suggested for PA resistant to classical PA 
therapies, in which the resistance to SS and DA agonists is associated to different miRNA 
expression (Bottoni et al., 2007; Mao et al., 2010). 
5. Familial pituitary adenomas  
The vast majority of pituitary adenomas occur spontaneously, which means that they are 
not inherited, while familial pituitary tumours account for approximately 5% of all pituitary 
adenomas (Marx & Simonds, 2005). These tumours arise as a component of endocrine-
related tumour syndromes, namely Multiple Endocrine Neoplasia type I (MEN1), Multiple 
Endocrine Neoplasia type IV (MEN4) and Carney complex (CNC), or, if the condition seems 
to affect only the pituitary gland, as Familial Isolated Pituitary Adenomas (FIPA).   
Different gene mutations have been identified in patients affected by familial pituitary 
adenomas. In highly penetrant conditions, affected individuals manifest the disease 
phenotype at a considerably younger age (on average 4 years) than their sporadic 
counterparts; this is due to the shorter time elapse before a “second hit” occurs in a 
predisposed tissue that already harbours a germline genetic defect. On the contrary, low-
penetrance alleles may be more common in the general population, since the presence of a 
predisposing allele does not necessarily cause a disease-associated phenotype, or it may be 
associated with age-related penetrance and gender-specific risks (Fearon, 1997; Nagy et al., 
2004).  
5.1 Multiple Endocrine Neoplasia type I (MEN1) 
MEN1 is an inherited autosomal dominant disorder that causes tumours in various 
endocrine glands (Brandi et al., 2001). MEN1 is sometimes called multiple endocrine 
adenomatosis or Wermer’s syndrome, after one of the first doctor recognised and described 
it. MEN1 is rare, occurring in about one in 30,000 people. The disorder affects both sexes 
equally and shows no geographical, racial, or ethnic preferences (Teh et al., 1998).  
The gene causing MEN1, identified in 1997, was located on chromosome 11q13, and consists 
of 10 exons that encode a 610-amino acid protein referred to as Menin (Teh et al., 2005). 
Menin is predominantly a nuclear protein that has roles in transcriptional regulation, 
genome stability, cell division and proliferation (Marx & Simonds, 2005). Thus, in 
transcriptional regulation, Menin interacts with the activating protein-1 (AP-1) transcription 
factors JunD and C-Jun, and members of the NF-kB family transcriptional regulators, to 
repress transcriptional activation; members of the Smad family, to inhibit the transforming 
growth factor- (TGF-) and the bone morphogenetic protein-2 (BMP-2) signalling 
pathways. A wider role in transcription regulation has also been suggested, as Menin has 
been shown to be an integral component of histone methyltransferase complexes (Agarval et 
al., 2004). 
MEN1 tumours frequently have LOH of the MEN1 locus, which is consistent with a tumour 
suppressor role of MEN1. Also mutations of the MEN1 gene have been identified, and, to 
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date, about 1300 mutations have been reported: approximately 23% are nonsense mutations, 
around 41% are frameshift deletions or insertions, 6% are in-frame deletions or insertions, 
9% are splice-site mutations, 20% are missense mutations, and 1% are whole or particular 
gene deletions. The majority (>70%) of these mutations are predicted to lead to truncated 
forms of Menin disrupting the interactions of Menin with other proteins and altering critical 
events in cell cycle regulation and proliferation. However, a comparison of the clinical 
features in patients and their families with the same mutations reveals an absence of 
phenotype–genotype correlations (Lemos & Thakker, 2008).  
In patients with MEN1, several endocrine glands form tumours and become hormonally 
overactive (Brandi et al., 2001). In MEN1, the overactive glands most often include the 
parathyroid glands, the pancreas and the pituitary. The parathyroids are the endocrine 
glands earliest and most often affected by MEN1. In MEN1 patients, all four parathyroid 
glands tend to be overactive, causing hyperparathyroidism. The parathyroid glands form 
tumours that release too much PTH, leading to hyper-calcemia. People with MEN1 have 
about a 20 to 60 percent chance of developing gastrinomas. Gastrin is a hormone that 
stimulates secretion of gastric acid (HCl) by the parietal cells of the stomach and aids in 
gastric motility. The pituitary gland develops a tumour in about one in four people with 
MEN1. This tumour most often releases too much prolactin, developing a prolactinoma. 
High prolactin levels can cause excessive production of breast milk or interfere with fertility 
in women or with sex drive and fertility in men. Other pituitary tumour types in MEN1 can 
be NFPA or GH-secreting adenoma. 
5.2 The novel Multiple Endocrine Neoplasia type IV (MEN4) syndrome  
Recently, it has been recognized a new rare type MEN1-like syndrome named Multiple 
Endocrine Neoplasia type 4 (MEN4) caused by mutation of CDKN1B (Pellegata et al., 2006). 
This gene, which maps at 12p13 locus, codes for the 196 amino acid cyclin-dependent kinase 
inhibitor p27kip1. CDKN1B/p27Kip1 protein plays an important role in the cell cycle 
regulation, through the binding and inhibition of cyclin/CDK complexes during the cellular 
G1 to S phase transition (Sherr & Roberts, 1999); thus, CDKN1B/p27Kip1 participates in 
determining several cell fate decisions, including proliferation, differentiation, apoptosis, 
cell density, and even cell migration (Besson et al., 2004; Chu et al., 2008). The CDKN1B 
changes so far identified in MEN4 patients either affect the localization, the stability or the 
protein binding abilities of p27kip1. Interestingly, it has been shown that CDKN1B is a 
transcriptional gene target of Menin (Karnik et al., 2005). These findings point to a critical 
role for p27-mediated cell cycle regulation in neuroendocrine cell homeostasis.  
Six germline mutations have been identified so far. Two of them determine a truncated 
protein with an aberrant cytoplasmic localization. Other two mutations are located in p27kip1 
region involved in the binding to Grb2 or CDK2. Another one is in the p27kip1 regulatory 
region at –7 position of the Kozak sequence, and is associated with reduction in p27kip1 
protein levels. Lastly, a mutation at stop codon to Q, coding for an aberrant longer p27kip1 
including 60 aa more in comparison with the wild-type protein, has been recently identified 
(Molatore & Pellegata, 2010). Bi-allelic inactivation of CDKN1B is an exceedingly rare 
condition in human tumours, which usually exhibit hemizygous loss of the locus. Therefore, 
the finding that tumours in CDKN1B mutation carriers show loss of heterozygosity or lack 
of p27kip1 expression suggests that p27kip1 may behave as a ‘canonical’ tumour suppressor in 
neuroendocrine cells.  
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The phenotypic features associated with MEN4 are still undefined due to the small number 
of patients reported so far. It is worth noting that these families do not exhibit significant 
phenotypic differences when compared to MEN1 mutation-positive families (Bassett et al., 
1998).  
5.3 Carney complex (CNC) 
Carney complex is a hereditary condition. It is associated with spotty skin pigmentation, 
myxomas (benign or non cancerous connective tissue tumours), and benign or cancerous 
tumours of the endocrine glands such as the adrenal (Cushing’s syndrome), thyroid and 
pituitary gland (GH-secreting tumours). Although people with Carney complex have an 
increased risk of cancer, most tumours are benign. 
About 60% of people with Carney complex have a mutation in the CNC1 locus, which maps 
on chromosome 17q24 (Stratakis et al., 1996). This locus was found to harbour the 
predisposing gene protein kinase A type I-alpha regulatory subunit (PRKAR1A), encoding a 
serine/threonine protein kinase A (PKA) regulatory subunit that is the main mediator in 
cAMP signalling. The function of PRKAR1A is to bind cAMP and regulate the function of 
the catalytic subunits of the protein kinase A (PKA) holoenzyme. Inactivating PRKAR1A 
mutations have been identified in up to 60% of CNC patients meeting the diagnostic criteria 
(Kirschner et al., 2000). Almost all 40 distinct germline PRKAR1A mutations reported so far 
lead to mRNA instability, abnormal PRKAR1A and increased PKA activity with elevated 
cAMP levels in the affected tissues (Groussin et al., 2002), leading to typical manifestations 
of CNC. However, it is likely that other genes may be associated with Carney complex. 
Indeed, many of CNC tumours show amplification or deletion of the 2p16 region (the CNC2 
locus) (Matyakhina et al., 2003). 
Carney complex follows an autosomal dominant inheritance pattern, in which a mutation 
happens in only one copy of the gene. It is estimated that between 50% and 70% of cases of 
Carney complex are familial, while the remaining 30% to 50% of cases result from new 
mutations.  
5.4 Familial Isolated Pituitary Adenomas (FIPA) 
Recently, a distinct clinical entity, namely Familial Isolated Pituitary Adenomas (FIPA), has 
been reported. It characterizes families with isolated pituitary adenomas outside the clinical 
and genetic contexts of MEN1 and CNC (Daly et al., 2005).  
The pituitary tumour types occurring in these families are most commonly GH-secreting 
adenomas (causing acromegaly or acromegalic gigantism), prolactinomas or NFPA, very 
rarely ACTH-secreting adenomas (causing Cushing's disease) or TSH-secreting adenomas 
(Daly et al., 2006). The disease most often starts in adulthood, very rarely in childhood.  
The gene responsible for this familial disease has been identified in only 20% of the families. 
It is called Aryl hydrocarbon receptor (AHR) Interacting Protein, in short AIP, which is part 
of AHR pathway (Daly et al., 2007). AIP gene is located on chromosome 11q13, and its 
product is a member of the immonophilin family of proteins with three tetraicopeptide 
repeats, the TPR domains, that act as scaffolds for the assembly of different multi-protein 
complexes. AHR is a ligand-inducible transcription factor that mediates the cellular 
response to xenobiotic compounds. Upon ligand binding, AHR is activated by a 
conformation change that exposes a nuclear localization signal: the receptor translocates to 
the nucleus, where it binds to aryl hydrocarbon receptor nuclear translocator. The 
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heterodimer binds to the xenobiotic response element and regulates gene expression.  Loss 
of heterozygosity of AIP gene has been found in tumours of FIPA patients. According to the 
Knudson two-hit hypothesis, the first hit is due to an inherited germline mutation of one 
allele and the second hit is a somatic deletion of the other allele (Knudson, 2001).  
Almost 50 different germline AIP mutations have been demonstrated in the setting of FIPA. 
Most of them are present in the TPR domain. Other nonsense and missense mutations all 
along the coding sequence have been described (Beckers & Daly, 2007). The appearance of PA 
occurs earlier in the patients carrying AIP mutations with respect to the AIP negative patients. 
In FIPA families with normal AIP, a linkage with loci 2p16, 3q28, 4q32.3–4q33, 8q12.1, 
19q13.4, and 21q22.1 has been shown, suggesting that mutations in several other genes may 
be involved in the development of FIPA syndrome (Toledo et al., 2010). 
 
Adenoma type Incidence Mutated gene Syndrome 
GH-secreting 
PRL-secreting 
NFPA 
10% 
30% 
5% 
MEN1 
Multiple endocrine 
neoplasia type 1 
(MEN1) 
To be defined To be defined CDKN1B 
Multiple endocrine 
neoplasia type IV 
(MEN4) 
GH secreting 
GH-PRL secreting 
15% 
70% 
PRKAR1A 
CNC2 locus 
Carney complex 
(CNC) 
GH-secreting 
PRL-secreting 
NFPA 
30% 
40% 
13% 
AIP FIPA 
Table 4. Familial pituitary adenomas. 
6. Conclusions 
Based on all the events associated with the pathogenesis of PA, the sequence of genetic 
alterations likely begins, at least for GH-secreting adenomas, with an aberrant cAMP 
signalling that causes polyclonal hyperplasia and/or initial adenoma formation (as 
evidenced by GNAS and PRKAR1A involvement). Then, for all subtypes, growth of a 
monoclonal pituitary tumour is initiated and/or assisted by cell-cycle dysregulation and 
aneuploidy. Menin down-regulation, methylation of certain target genes, aneuploidy 
and/or disruption of genomic integrity in a greater scale lead to a well-growing pituitary 
adenoma, but still responsive to medical and/or surgical treatment (depending on the type). 
Finally, E2F1 activation, cell cycle dysregulation, PTTG over-expression and/or additional 
growth factor up-regulation and increased angiogenesis lead to aggressive tumours. 
However, mitotic activity is low even in aggressive PA, in contrast to tumours arising from 
more rapidly replicating tissues, and pituitary tumours rarely progress to carcinoma 
(Chesnokova & Melmed, 2010). 
Indeed, induction of premature senescence in PA, which is triggered in response to 
aneuploidy, restrains further growth and malignant transformation but allows the cells to 
remain viable and perform their physiological functions. 
Anyway, further studies are required to better understand all the genetic and epigenetic 
alterations accounting for the development of PA and the sequence with which they occur.  
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